Modern Era2023-present

The Rescheduling Debate: Schedule III Proposal & DEA Review

The history of cannabis rescheduling from Schedule I to Schedule III — HHS recommendation, DEA review, and the potential impact on the cannabis industry and federal policy.

2023-present

Time Period

Historical era

Key Figures

Historical actors

Sections

In-depth coverage

FAQs

Common questions

Overview

In August 2023, the Department of Health and Human Services (HHS) formally recommended that the DEA reschedule cannabis from Schedule I to Schedule III of the Controlled Substances Act — the most significant federal cannabis policy development in over fifty years. The recommendation followed a scientific review by the FDA that concluded cannabis has accepted medical use, a lower potential for abuse than Schedule I and II substances, and a moderate risk of physical dependence. Rescheduling to Schedule III would not legalize recreational cannabis, but its effects would be profound. Most immediately, it would eliminate IRC Section 280E, a tax provision that prevents cannabis businesses from deducting ordinary business expenses, resulting in effective tax rates of 50-70% for many operators. Schedule III classification would also ease research barriers, allow cannabis companies to access normal business deductions, and represent a symbolic federal acknowledgment that cannabis has legitimate medical value. The DEA initiated a formal rulemaking process in 2024, including a public comment period that received unprecedented engagement. The process has been closely watched by the cannabis industry, with publicly traded cannabis stocks experiencing significant price movements in response to each development. As of 2026, the rescheduling process continues to advance through federal administrative procedures.

The rescheduling process began in October 2022, when President Biden directed HHS and the Attorney General to review marijuana's scheduling. This followed Biden's mass pardon of federal simple marijuana possession convictions and reflected evolving political calculations about cannabis policy. Biden, who had authored the 1994 crime bill and long opposed legalization, had gradually moderated his position in response to shifting public opinion and advocacy from within his own party.

The FDA's scientific review, completed in early 2023, applied the same eight-factor analysis used for any scheduling recommendation. The review concluded that cannabis met the criteria for Schedule III: it had accepted medical use in the United States (evidenced by state medical programs serving millions of patients), a lower potential for abuse than Schedule I and II substances, and a currently accepted medical use in treatment. The FDA's recommendation to HHS was based on scientific evidence rather than political considerations.

The elimination of Section 280E would be the most immediate financial impact of rescheduling. Under current law, cannabis businesses cannot deduct rent, payroll, utilities, or other ordinary expenses — deductions available to every other legal business in America. This results in effective tax rates of 50-70% for many operators. Moving to Schedule III would allow normal business deductions, potentially saving the industry billions of dollars annually and transforming the financial viability of many cannabis companies.

Research access would improve significantly under Schedule III. Currently, researchers studying marijuana must obtain DEA Schedule I research licenses, use cannabis from a single federally authorized source, and navigate years-long approval processes. Schedule III classification would dramatically simplify this process, allowing researchers to study cannabis with the same regulatory framework that applies to ketamine, anabolic steroids, and Tylenol with codeine.

The DEA's rulemaking process has proceeded through multiple stages. After receiving the HHS recommendation, the DEA published a Notice of Proposed Rulemaking in the Federal Register, opening a public comment period. The agency received hundreds of thousands of comments from patients, industry participants, medical professionals, law enforcement, and the general public. An administrative law judge conducted hearings to evaluate the evidence and testimony.

The cannabis industry has responded to rescheduling developments with significant market movements. Multi-state operator (MSO) stocks rallied 30-50% following the initial HHS recommendation in August 2023 and experienced further volatility around each subsequent milestone. Analysts estimated that 280E relief alone could increase industry EBITDA by 25-40%, making rescheduling arguably the single most valuable near-term catalyst for cannabis investors. However, uncertainty about the timeline and final outcome has kept cannabis valuations well below levels implied by full rescheduling.

Key Figures

Joe Biden

President who directed the scheduling review

Xavier Becerra

HHS Secretary who oversaw the department's recommendation

Anne Milgram

DEA Administrator overseeing the rulemaking process

Robert Califf

FDA Commissioner whose agency conducted the scientific review

Historical Significance

The HHS recommendation to reschedule cannabis to Schedule III represents the most significant federal cannabis policy shift in over 50 years, potentially eliminating 280E tax burdens, easing research barriers, and formally acknowledging medical value.

Frequently Asked Questions

What does rescheduling cannabis to Schedule III mean?

Rescheduling from Schedule I to III would acknowledge that cannabis has accepted medical use, moderate abuse potential, and would remove it from the most restrictive drug category. It would not legalize recreational use but would eliminate 280E tax burdens, ease research, and provide symbolic federal recognition of medical cannabis.

What is Section 280E and how does it affect cannabis?

IRC Section 280E prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. Cannabis companies cannot deduct rent, payroll, or utilities, resulting in effective tax rates of 50-70%. Moving to Schedule III would eliminate this burden, potentially saving the industry billions annually.

Would rescheduling legalize marijuana?

No. Schedule III substances like ketamine and anabolic steroids are legal only with a prescription. Rescheduling would acknowledge medical use and reduce regulatory burden but would not legalize recreational sale or possession. Full legalization would require either descheduling or new federal legislation.

How would rescheduling affect cannabis stocks?

Analysts estimate that 280E relief from rescheduling could increase industry EBITDA by 25-40%. MSO stocks have rallied 30-50% on positive rescheduling developments. However, the full impact depends on the final rule's details, implementation timeline, and whether additional regulatory requirements accompany Schedule III classification.